4,4-dimethyl thiachromane | 20262-71-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 硫铬烷
• 英文名称: 4,4-dimethyl thiachromane
• 英文别名: 2,2-dimethyl-thiochroman；2,2-dimethylthiochroman；2,2-Dimethylthiachroman；2,2-dimethyl-3,4-dihydrothiochromene
• CAS: 20262-71-9
• 化学式: C₁₁H₁₄S
• 分子量: 178.298
• InChiKey: GJIWERBRSHMVAU-UHFFFAOYSA-N

物化性质

• 沸点：
  255.6±10.0 °C(Predicted)
• 密度：
  1.023±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-methyl-4-((2-methylbut-3-en-2-yl)sulfonyl)benzene 、 苯硫酚 在 magnesium bromide 作用下， 以 甲苯 为溶剂， 反应 18.0h， 以60%的产率得到4,4-dimethyl thiachromane
  参考文献：
  名称：

  Julia, Marc; Nel, Maurice; Uguen, Daniel, Bulletin de la Societe Chimique de France, 1987, # 3, p. 487 - 492

  摘要：

  DOI：

文献信息

• [EN] METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE LA MÉTHYLAMINE COMME INHIBITEURS DE LA LYSYL OXIDASE POUR LE TRAITEMENT DU CANCER
  申请人：THE INST OF CANCER RESEARCH: ROYAL CANCER HOSPITAL

  公开号：WO2017141049A1

  公开（公告）日：2017-08-24

  Provided are compounds of the Formula (I), or a pharmaceutically acceptable salt thereof, wherein W, X, Y, Z, x, R1, R2, R3, x and n are defined in the specification. The compounds are inhibitors of lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family members (LOXL1, LOXL2, LOXL3, LOXL4) and are useful in therapy, particularly in the treatment of cancer. Also disclosed are LOX inhibitors for use in the treatment of a cancer associated with EGFR and biomarkers that predict responsiveness to a LOX inhibitor.

  提供的是Formula (I)的化合物，或其药用可接受的盐，其中W、X、Y、Z、x、R1、R2、R3、x和n在规范中有定义。这些化合物是赖氨酸氧化酶（LOX）和赖氨酸氧化酶样（LOXL）家族成员（LOXL1、LOXL2、LOXL3、LOXL4）的抑制剂，并且在治疗中很有用，特别是在癌症治疗中。还披露了用于治疗与EGFR相关的癌症的LOX抑制剂，以及预测对LOX抑制剂响应性的生物标志物。
• Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
  申请人：Boehm F. Marcus

  公开号：US20060106072A1

  公开（公告）日：2006-05-18

  Compounds, compositions, and methods for modulating processes mediated by Retinoid X Receptors using retinoid-like compounds which have activity selective for members of the subclass of Retinoid X Receptors (RXRs), in preference to members of the subclass of Retinoic Acid Receptors (RARs). Examples of such compounds are bicyclic benzyl, pyridinyl, thiophene, furanyl, and pyrrole derivatives. The disclosed methods employ compounds for modulating processes selectively mediated by Retinoid X Receptors.

  本发明涉及利用类视黄醇化合物调节由视黄酸X受体介导的过程的复合物、组合物和方法，其中这些类视黄醇化合物具有对视黄酸X受体亚类（RXRs）的选择性活性，而不是对视黄酸受体亚类（RARs）的选择性活性。此类化合物的例子包括双环苄基、吡啶基、噻吩基、呋喃基和吡咯基衍生物。所披露的方法利用这些化合物来调节由视黄酸X受体选择性介导的过程。
• Compounds having selectivity for retinoid x receptors
  申请人：LIGAND PHARMACEUTICALS, INC.

  公开号：EP0983991A2

  公开（公告）日：2000-03-08

  Compounds, compositions, and method for modulating processes mediated by Retinoid X Receptors using retinoid-like compounds which have activity selective for members of the subclass of Retinoid X Receptors (RXRs), in preference to members of the subclass of Retinoic Acid Receptors (RARs). Examples of such compounds are bicyclic benzyl, pyridinyl, thiophene, furanyl, and pyrrole derivatives. The disclosed methods employ compounds for modulating processes selectively mediated by Retinoid X Receptors.

  利用对视黄醇 X 受体（RXRs）亚类成员具有选择性活性的视黄醇样化合物，优先于视黄酸受体（RARs）亚类成员，调节视黄醇 X 受体介导的过程的化合物、组合物和方法。此类化合物的例子有双环苄基、吡啶基、噻吩基、呋喃基和吡咯衍生物。所公开的方法采用化合物来调节由视黄酸 X 受体选择性介导的过程。
• PYRIDYLPYRROLE DERIVATIVES
  申请人：Sankyo Company Limited

  公开号：EP1031572A1

  公开（公告）日：2000-08-30

  Object: to provide compounds having an inhibitory effect on the production of inflammatory cytokines. Constitution: compounds having general formula (I), pharmacologically acceptable salts thereof or derivatives of the same, wherein A: single bond, oxygen, sulfur, CO, SO, SO2, C(R9)(R10) [R9, R10: H, OH, halogeno, alkyl], N(R11), C=NOR11 [R11: H, alkyl]; D: single bond, C(R12)(R13) [R12, R13: H, OH, halogeno, alkyl]; R1 : optionally substituted pyridyl; R2 : optionally substituted phenyl; R3 : halogeno, alkyl, haloalkyl, alkoxy, haloalkoxy; R4, R5, R6, R7, R8 : H, alkyl; k: 0-3; and m: 1, 2.

  目的：提供对炎症细胞因子的产生具有抑制作用的化合物。构成：具有通式（I）的化合物、其药理学上可接受的盐或其衍生物，其中A：单键、氧、硫、CO、SO、SO2、C(R9)(R10)[R9、R10：H、OH、卤代、烷基]、N(R11)、C=NOR11[R11：H、烷基]；D：单键、C(R12)(R13) [R12、R13：H、OH、卤代物、烷基]；R1：任选取代的吡啶基；R2：任选取代的苯基；R3：卤代物、烷基、卤代烷基、烷氧基、卤代烷氧基；R4、R5、R6、R7、R8：H、烷基；k：0-3；m：1、2。
• Polymerizable composition and optically anisotropic body using same
  申请人：DIC CORPORATION

  公开号：US10479844B2

  公开（公告）日：2019-11-19

  The present invention provides a polymerizable composition containing a specific polymerizable compound and a fluorosurfactant having a specific polyoxyalkylene skeleton and having specific molecular weight. The invention also provides an optically anisotropic body, a retardation film, an antireflective film, and a liquid crystal display device that are produced using the polymerizable composition of the present invention. The present invention is useful because, when an optically anisotropic body is produced by photo-polymerization of the polymerizable composition, three features including the leveling properties of the surface of the optically anisotropic body, offset onto the substrate, and liquid crystal alignment can be improved simultaneously.

  本发明提供了一种可聚合组合物，其中含有特定的可聚合化合物和具有特定聚氧亚烷基骨架并具有特定分子量的含氟表面活性剂。本发明还提供了使用本发明的可聚合组合物生产的光学各向异性体、延缓膜、抗反射膜和液晶显示装置。本发明之所以有用，是因为当通过可聚合组合物的光聚合作用生产出光学各向异性体时，可同时改善光学各向异性体表面的平整性、偏移到基板上的偏移量和液晶排列等三个特性。